Targeted Cancer Therapy and Mechanisms of Resistance / / Valentina de Falco, editor.
Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called "oncogene addiction". According to this concept, protein kinases have been identified as promising molecular targets for ca...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | [Place of publication not identified] : : MDPI - Multidisciplinary Digital Publishing Institute,, 2022. |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 online resource (280 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993603389504498 |
---|---|
ctrlnum |
(CKB)5400000000045823 (NjHacI)995400000000045823 (EXLCZ)995400000000045823 |
collection |
bib_alma |
record_format |
marc |
spelling |
Targeted Cancer Therapy and Mechanisms of Resistance / Valentina de Falco, editor. [Place of publication not identified] : MDPI - Multidisciplinary Digital Publishing Institute, 2022. 1 online resource (280 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on publisher supplied metadata and other sources. Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called "oncogene addiction". According to this concept, protein kinases have been identified as promising molecular targets for cancer therapy. There are several possibilities for targeting these proteins in cancer, including monoclonal antibodies, compounds able to favor the proteolytic degradation of the kinase, small-molecule protein kinase inhibitors (PKIs). Moreover, new anticancer treatments have increasingly been developed focusing on tumor suppressor genes and RNA interference. Despite promising results in cancer treatment with targeted cancer drugs, clinical experience has shown that only a fraction of patients respond to targeted therapies, even if their tumor expresses the altered target. This is known as primary resistance. Otherwise, secondary or acquired resistance to the treatment arises, almost invariably, when tumors are treated with cancer drugs. We set out to select some studies containing emerging developments on the subject. In essence, this collection aims to highlight some recent findings regarding resistance mechanisms and reviews of molecular targeting and resistance with 14 contributions, including 10 original research papers and 4 reviews. Aspects relating to solid cancers, such as breast, ovary, colon, and blood cancers such as leukemia, and the identification of resistance mechanisms and new molecular targets, help to create the basis for the preclinical and clinical development of more effective next-generation drugs. Medicine. Medical sciences. 3-0365-2857-1 de Falco, Valentina, editor. |
language |
English |
format |
eBook |
author2 |
de Falco, Valentina, |
author_facet |
de Falco, Valentina, |
author2_variant |
f v d fv fvd |
author2_role |
TeilnehmendeR |
title |
Targeted Cancer Therapy and Mechanisms of Resistance / |
spellingShingle |
Targeted Cancer Therapy and Mechanisms of Resistance / |
title_full |
Targeted Cancer Therapy and Mechanisms of Resistance / Valentina de Falco, editor. |
title_fullStr |
Targeted Cancer Therapy and Mechanisms of Resistance / Valentina de Falco, editor. |
title_full_unstemmed |
Targeted Cancer Therapy and Mechanisms of Resistance / Valentina de Falco, editor. |
title_auth |
Targeted Cancer Therapy and Mechanisms of Resistance / |
title_new |
Targeted Cancer Therapy and Mechanisms of Resistance / |
title_sort |
targeted cancer therapy and mechanisms of resistance / |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute, |
publishDate |
2022 |
physical |
1 online resource (280 pages) |
isbn |
3-0365-2857-1 |
callnumber-first |
R - Medicine |
callnumber-subject |
R - General Medicine |
callnumber-label |
R129 |
callnumber-sort |
R 3129 T374 42022 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
610 - Medicine & health |
dewey-full |
610.951 |
dewey-sort |
3610.951 |
dewey-raw |
610.951 |
dewey-search |
610.951 |
work_keys_str_mv |
AT defalcovalentina targetedcancertherapyandmechanismsofresistance |
status_str |
n |
ids_txt_mv |
(CKB)5400000000045823 (NjHacI)995400000000045823 (EXLCZ)995400000000045823 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Targeted Cancer Therapy and Mechanisms of Resistance / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796653225712025600 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02665nam a2200301 i 4500</leader><controlfield tag="001">993603389504498</controlfield><controlfield tag="005">20230630212159.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230630s2022 xx o 000 0 eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/books978-3-0365-2856-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000045823</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995400000000045823</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000045823</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">R129</subfield><subfield code="b">.T374 2022</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610.951</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Targeted Cancer Therapy and Mechanisms of Resistance /</subfield><subfield code="c">Valentina de Falco, editor.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Place of publication not identified] :</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (280 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called "oncogene addiction". According to this concept, protein kinases have been identified as promising molecular targets for cancer therapy. There are several possibilities for targeting these proteins in cancer, including monoclonal antibodies, compounds able to favor the proteolytic degradation of the kinase, small-molecule protein kinase inhibitors (PKIs). Moreover, new anticancer treatments have increasingly been developed focusing on tumor suppressor genes and RNA interference. Despite promising results in cancer treatment with targeted cancer drugs, clinical experience has shown that only a fraction of patients respond to targeted therapies, even if their tumor expresses the altered target. This is known as primary resistance. Otherwise, secondary or acquired resistance to the treatment arises, almost invariably, when tumors are treated with cancer drugs. We set out to select some studies containing emerging developments on the subject. In essence, this collection aims to highlight some recent findings regarding resistance mechanisms and reviews of molecular targeting and resistance with 14 contributions, including 10 original research papers and 4 reviews. Aspects relating to solid cancers, such as breast, ovary, colon, and blood cancers such as leukemia, and the identification of resistance mechanisms and new molecular targets, help to create the basis for the preclinical and clinical development of more effective next-generation drugs.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medicine.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medical sciences.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2857-1</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Falco, Valentina,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-07-08 12:19:40 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338078700004498&Force_direct=true</subfield><subfield code="Z">5338078700004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338078700004498</subfield></datafield></record></collection> |